The Challenge
Helen's family came with a list of disparate treatment ideas after her glioblastoma diagnosis, struggling to interpret a rare RET mutation and balance trial options, off-label therapies, and quality-of-life goals.
Our Impact
Cancer Commons explained the molecular findings, confirmed the RET variant with expert review from a clinical genomics scientist, compared trial and off-label approaches, and helped the family create a clear plan of treatment plus a carefully monitored ketogenic program to fit Helen's goals.
The Outcome
The family felt informed, unified, and supported, confident that Helen's care plan reflected both the science and their shared priorities for safety and quality of life.
